Drugs / ELGEMTUMAB
Trials 6
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 15 trials | ||||||
| Phase 1 | NCT02167854 | Jun 2014 → Jul 2021 | breast cancer | Memorial Sloan Kettering Cancer Center | Completed | No outcome recorded |
| Phase 1 | NCT01911936 | Sep 2013 → Mar 2015 | neoplasm | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 1 | NCT01822613 | Jul 2013 → Jun 2016 | esophageal squamous cell carcinoma | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 1 | NCT01602406 | Sep 2012 → Aug 2017 | HER2 positive breast carcinoma | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 1 | NCT01598077 | Jul 2012 → Mar 2014 | HER2 positive breast carcinoma, esophageal squamous cell carcinoma, head and neck squamous cell carcinoma | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT02143622 | Mar 2015 → Aug 2018 | head and neck squamous cell carcinoma | Novartis Pharmaceuticals | Withdrawn | No outcome recorded |
Evidence & citations 8 cited values
Every value below carries the sentence it was read from. 8 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ELGEMTUMAB | ChEMBL registry synonym — accepted as the source's own label CHEMBL4298013 ↗ |
| Known as | 69745p00p9 | ChEMBL registry synonym — accepted as the source's own label CHEMBL4298013 ↗ |
| Known as | LJM716 | “LJM716 is a human IgG monoclonal antibody that binds HER3, trapping it in an inactive conformation.” PMID 27942917 ↗ Dec 2016 |
| Known as | NOV-6 | ChEMBL registry synonym — accepted as the source's own label CHEMBL4298013 ↗ |
| Action | Inhibit | “Receptor tyrosine-protein kinase erbB-3 inhibitor” CHEMBL4298013 ↗1“trapping it in an inactive conformation” PMID 27942917 ↗ Dec 2016 |
| Modality | Monoclonal antibody | “anti-HER3 monoclonal antibody” PMID 28899363 ↗ Sep 2017 |
| Route | Intravenous | “given by IV infusion” NCT01598077 ↗ |
| Target | ERBB3 | “Receptor tyrosine-protein kinase erbB-3 inhibitor” CHEMBL4298013 ↗ |